Project Grant R01HL173578
Award Date
4/15/25
Completion Date
2/28/29
Dollars Obligated
$719K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
California, USA
Similar Awards
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $733,805 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to The Regents of the University of California, San Francisco (UCSF) to conduct a 6-month randomized controlled trial. The objective is to test the efficacy of a virtual coaching and social support intervention to improve physical activity (PA), psychosocial, social cognitive, and clinical outcomes for older adults (age 60+) exiting cardiac rehabilitation and...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $433,824 Project Grant under the Cardiovascular Diseases Research Program (CFDA 93.837) to The Leland Stanford Junior University. The grant, which runs from September 6, 2024 to March 31, 2026, supports research to understand the metabolic interplay between different cell types (cardiomyocytes, endothelial cells, fibroblasts) in a human induced pluripotent stem cell (iPSC) model of diabetic cardiomyopathy. The project aims to...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $159,512 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The Leland Stanford Junior University, also known as Stanford University. The grant supports research to investigate the role of the unfolded protein response in genetic dilated cardiomyopathy, a leading cause of heart failure. The project will utilize induced pluripotent stem cell-derived cardiomyocytes carrying DCM mutations to study the...
The National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), has awarded a $789,026 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Beth Israel Deaconess Medical Center, Inc. (Bidmc) to evaluate the long-term effectiveness and value of cardiac rehabilitation (CR) in diverse populations. The key products and services to be delivered under this 4-year project include: Leveraging large, linked datasets and novel causal...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $753,813 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to Yale University to develop machine learning techniques that can predict cardiovascular outcomes in patients with clonal hematopoiesis of indeterminate potential (CHIP). The research aims to create a risk assessment tool that integrates cardiac MRI data, genomic signatures, and clinical data to identify CHIP patients at risk of developing heart failure or...
The National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research Federal Grant Program (CFDA 93.837), awarded a $299,604 Project Grant to Case Western Reserve University (CWRU) to develop and validate a novel "transfer volume regression" machine learning model for predicting major cardiovascular events, including stroke, heart attack, heart failure, and death. The 4-year project, starting September 1, 2024, aims to create a standardized, fairness-aware,...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), part of the Cardiovascular Diseases Research program (CFDA 93.837), aims to evaluate the AMPK-BACH1-NRF2 signaling pathway as a potential therapeutic target for treating inherited dilated cardiomyopathy (DCM), a leading cause of heart failure. The $1,204,160 grant, awarded on July 16, 2024, will support research at The Leland Stanford Junior University to explore the selectivity of this pathway for...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $1,102,957 to The Leland Stanford Junior University to conduct comprehensive research on the links between cancer and cardiovascular disease. The research aims to precisely determine if cancer directly promotes cardiovascular disease and identify potential therapies to treat patients with co-occurring conditions. The interdisciplinary...
The Leland Stanford Junior University (Stanford University) was awarded a $2,996,098 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research Federal Grant Program (CFDA 93.837). The grant aims to develop a multi-physics simulator for pediatric cardiac surgical planning, focused on addressing the critical need to improve outcomes for patients with complex congenital heart disease, specifically those with single ventricle physiology....
The National Heart, Lung, and Blood Institute (NHLBI) awarded the University of California, Davis (UC Davis) a $790,432 Project Grant under CFDA 93.837, the Cardiovascular Diseases Research program. The project, titled "Digital Twins from the Atom to the Rhythm," aims to develop a transformative integrative pipeline to create digital twin technology for patient-specific disease prediction and drug efficacy evaluation. The research will combine atomistic-scale protein simulations,...